Start Free Trial
Pricing
Log In
Log In
Upgrade browser for full Crunchbase experience. You're accessing Crunchbase in a browser that is no longer supported.
Learn More
BioVaxys Logo
BioVaxys Growth Score
49
CB Rank
189170
Heat Score
45
BioVaxys is a clinical stage biotechnology company developing immunotherapeutic cancer vaccines targeting melanoma.
Founded
obfuscation
PublicPost-IPO Equity Etobicoke, Ontario, Canada1-10 biovaxys.com/
Biopharma
Biotechnology
Overview

BioVaxys
Total Funding
obfuscation
Growth Score
49
Heat Score
45

Total Funding
obfuscation
obfuscation
Post-IPO Equity raised
obfuscation
Growth Score49
-32 pts
in past quarter
Heat Score 45
-6 pts
in past quarter

Company Performance Metrics

Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Learn More >
See more interactive data and historical milestones on desktop for the best experience

About BioVaxys

CB Rank
189170
BioVaxys is a clinical stage biotechnology company developing immunotherapeutic cancer vaccines targeting melanoma.
Founded
obfuscation
PublicPost-IPO Equity Etobicoke, Ontario, Canada1-10 biovaxys.com/
Biopharma
Biotechnology

Funding Rounds

Post-IPO Equity
OBF
in
obfuscation
Post-IPO Debt
OBF
in
obfuscation
Post-IPO Equity
OBF
in
obfuscation

Key People

Details

Legal Name BioVaxys Technology Corp.
Also Known As BioVaxys Technology
Operating Status Active
Stock Symbol  CNSX:BIOV
Company Type For Profit
Founders  David Berd, James Passin, Kenneth Kovan
About the Company

BioVaxys Technology Corp. is a British Columbia-registered, early stage biotechnology company that is developing viral and oncology vaccine platforms, as well as immuno-diagnostics. The Company is advancing a SARS-CoV-2 vaccine based on its haptenized viral protein technology, and is planning a clinical trial of its haptenized autologous cell

vaccine used in combination with anti-PD1 and anti-PDL-1 checkpoint inhibitors that will initially be developed for ovarian cancer. Also in development is a diagnostic for evaluating the presence or absence of a T cell immune response to SARS-CoV-2, the virus that causes COVID-19. BioVaxys has two issued US patents and two patent applications related to its cancer vaccine, and pending patent applications for its SARS-CoV-2 (Covid-19) vaccine and diagnostic technologies.

Phone Number 610 977 2440
Predictions & Insights

Growth Insight

See this Growth Insight
BioVaxys is
Lorem
 to be growing
Top Contributing Factors
Recently Raised Funding

Products & Services

BVX-0918 Ovarian Cancer Vaccine
A Phase I vaccine candidate using Haptenix© technology to enhance immune response against ovarian cancer by training T-cells to target tumor proteins.
DPX™ Delivery Platform
A lipid-based, non-aqueous delivery system designed to encapsulate various bioactive molecules to induce targeted and sustained immune responses.

Unlock More with Crunchbase Pro
  • Full access to financial & funding data on unlimited profiles
  • Export up to 2k results/month for analysis
  • Track market signals on competitors, products, and R&D
  • Preview private company insights and predictions
Financials

Company Funding

Total Funding Amount 
obfuscation
Number of Funding Rounds 19
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Post-IPO Equity - BioVaxys Logo
Post-IPO Equity - BioVaxys
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - BioVaxys Logo
Post-IPO Equity - BioVaxys
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - BioVaxys Logo
Post-IPO Equity - BioVaxys
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - BioVaxys Logo
Post-IPO Equity - BioVaxys
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - BioVaxys Logo
Post-IPO Equity - BioVaxys
—
obfuscation
— Post-IPO Equity

Funding Rounds

Total Funding Amount 
obfuscation
Number of Funding Rounds 19
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Post-IPO Equity - BioVaxys Logo
Post-IPO Equity - BioVaxys
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - BioVaxys Logo
Post-IPO Equity - BioVaxys
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - BioVaxys Logo
Post-IPO Equity - BioVaxys
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - BioVaxys Logo
Post-IPO Equity - BioVaxys
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - BioVaxys Logo
Post-IPO Equity - BioVaxys
—
obfuscation
— Post-IPO Equity

Investors

Unlock company funding data, including rounds, dates, amounts, and investors.
Investor Name  
Lead Investor  
Funding Round  
Partners  
Photo of James Passin
James Passin
—
Post-IPO Debt - BioVaxys Logo
Post-IPO Debt - BioVaxys
—
Photo of James Passin
James Passin
—
Post-IPO Debt - BioVaxys Logo
Post-IPO Debt - BioVaxys
—
Photo of James Passin
James Passin
—
Post-IPO Debt - BioVaxys Logo
Post-IPO Debt - BioVaxys
—
Photo of James Passin
James Passin
—
Post-IPO Debt - BioVaxys Logo
Post-IPO Debt - BioVaxys
—
Photo of James Passin
James Passin
—
Post-IPO Debt - BioVaxys Logo
Post-IPO Debt - BioVaxys
—

Investments

Number of Acquisitions 2

Investment Breakdown

Number of Acquisitions 2
Market Intelligence
People
View Profiles & Contacts
Headcount 1-10 Employee Profiles 3 Contacts 1

Employee Profiles

News

News and Press

News•Jan 8, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•Dec 17, 2025
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•Dec 17, 2025
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•Nov 19, 2025
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
Access a complete feed of recent news and press, from product launches to leadership changes.
Technology
View Tech Report

Monthly Web Visits

66
32%
 in past month

IT Spend

$179.3KThis year, BioVaxys is projected to spend $179.3K on IT, according to Aberdeen.

Active Website Tech Count

3BioVaxys is actively using 3 technologies for its website, according to BuiltWith. These include Euro and  CommonCrawl Top 10m.

Total IP

7BioVaxys has registered 7 trademarks with the most popular class being 'Pharmaceutical, veterinary and sanitary products', according to IPqwery.
Sub-Organizations
Frequently Asked Questions

Where is BioVaxys's headquarters? BioVaxys is located in Etobicoke, Ontario, Canada.Who invested in BioVaxys? BioVaxys has 3 investors including James Passin and  Kenneth Kovan.When was the last funding round for BioVaxys? BioVaxys closed its last funding round on
obfuscation
from a Post-IPO Equity round.Who are BioVaxys's competitors? Alternatives and possible competitors to BioVaxys may include Moderna, 3T Biosciences, and  Anocca.How much funding has BioVaxys raised to date? BioVaxys has raised
obfuscation
.
Who We Are
What We Do
Helpful Links
AI Content may contain mistakes and is not legal, financial or investment advice. Learn more.
Terms of Service | Privacy Policy | Sitemap | © 2026 Crunchbase Inc. All Rights Reserved.
(2e7868f 1)
|